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IL-6Adipokines such as leptin play important roles in the regulation of energymetabolism, particularly in the control
of appetite. Here, we describe a hormone, mimecan, which is abundantly expressed in adipose tissue. Mimecan
was observed to inhibit food intake and reduce body weight in mice. Intraperitoneal injection of a mimecan-
maltose binding protein (-MBP) complex inhibited food intake in C57BL/6J mice, which was attenuated by
pretreatment with polyclonal antibody against mimecan. Notably, mimecan-MBP also induced anorexia in Ay/a
and db/dbmice. Furthermore, the expression of interleukin (IL)-1β and IL-6was up-regulated in the hypothalamus
by mimecan-MBP, as well as in N9 microglia cells by recombinant mouse mimecan. Taken together, the results
suggest thatmimecan is a satiety hormone in adipose tissue, and thatmimecan inhibits food intake independently
of leptin signaling by inducing IL-1β and IL-6 expression in the hypothalamus.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mimecan, also known as an osteoinductive factor or osteoglycin, is a
12 kDa secreted protein corresponding to the 105 C-terminal amino
acids (residues 176–280) of the preproprotein encoded by the
osteoinductive factor gene (Oif), ﬁrst identiﬁed in the organic matrix
of bovine bone by chromatography (Bentz et al., 1989). Furthermore,
a 25 kDa keratin sulfate proteoglycan in bovine cornea was shown tof Medical Genomics, Molecular
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. This is an open access article underbe encoded by the cDNA of this gene, representing the 223 C-terminal
amino acids of the encoded protein (residues 58–280) (Funderburgh
et al., 1997). The full-length mimecan cDNA was identiﬁed from the
human pituitary, and was submitted to GenBank (accession no.
AF100758) in our previous study (Hu et al., 2000). The genomic struc-
ture of mimecan is highly conserved among different species. The
human mimecan precursor (298 amino acids) exhibits 92% homology
with bovine mimecan (299 amino acids), suggesting a functional im-
portance (Madisen et al., 1990). However, the physiological functions
of mimecan remain elusive. Several studies suggest mimecan may be
an essential component of normal vascular extracellular matrix, and it
is involved in atherosclerosis (Kampmann et al., 2009).Mimecan is con-
sidered a major putative regulator of the left ventricular mass (Petretto
et al., 2008), and the absence of mimecan has been observed in the de-
velopment of colorectal cancer (Wang et al., 2007). In our previous
study, mimecan was coexpressed with adrenocorticotropic hormone
(ACTH) in corticotroph cells of the pituitary, and was up-regulated by
glucocorticoids (Ma et al., 2010). Moreover, mimecan regulates ACTH
secretion in corticotroph cells, and may play roles in the coordination
of the hypothalamus–pituitary–adrenal axis (Ma et al., 2011). These
previous results suggest that mimecan is an important factor involved
in the physiological and biological functions. In the current study, we
report that mimecan is highly expressed in adipose tissue, and it acts
as a satiety factor inhibiting food intake by inducing interleukin
(IL)-1β and IL-6 expression in the hypothalamus.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Fusion Protein Puriﬁcation and Antibody Production
The cDNA encoding 12 kDa human mimecan (residues 175–279)
was subcloned into pGEX-5X-2 (GE Healthcare) and overexpressed in
Escherichia coli BL21 (DE3) cells. Puriﬁed mimecan-GST fusion protein
was used for antibody production. Rabbits and mice were immunized
with recombinant protein in Freund's adjuvant (Sigma-Aldrich, St.
Louis, MO, USA) for polyclonal andmonoclonal antibody production, re-
spectively. Antibodies were puriﬁed using Protein G (GE Healthcare).
The monoclonal subtype was identiﬁed as IgG1-κ. Human cDNA
encoding 12 kDa mimecan (residues 175–279) was subcloned into
pMAL-c2x (NEB) and overexpressed in BL21 (DE3) cells. Cells were
grown at 37 °C to an optical density at 595 nm(A595) of 0.6–0.8, induced
with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG) for 5 h, and centri-
fuged. Cells were sonicated, centrifuged, and the fusion protein in the
supernatant was puriﬁed by afﬁnity chromatography (MBPTrap HP,
GE Healthcare), gel ﬁltration (Superdex 200, 10/300 GL, GE Healthcare),
and ion exchange (HiTrap ANX FF, GE Healthcare) chromatography. Pu-
rity of the mimecan-MBP fusion protein was 96%, as determined by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and silver staining. MBP was expressed and puriﬁed (98%) for use as a
control. The cDNA encoding 25 kDa mimecan (residues 47–279) was
subcloned into pET-28a (+) (Novagen) and overexpressed in BL21
(DE3) cells. The mimecan-His fusion protein (Mim-His) was puriﬁed
(94%) by Ni-ion afﬁnity chromatography (HisTrap HP, GE Healthcare).
All proteins were buffer-exchanged with PBS, and endotoxin was
removed (ActiClean Etox, Sterogene, Carlsbad, CA, USA).
2.2. In Vivo Experiments
All animal experiments were conducted in accordance with the
institutional ethical guidelines on animal care, and approved by the
Shanghai Jiaotong University Animal Care and Use Committee. Animals
were housed individually for 1 week. C57BL/6J and Ay/a mice were
fasted overnight (8:00 p.m.–8:00 a.m.). Mim-MBP or Mim-His was
administered by i.p. injection. Nonfasted C57BL/6J mice were injected
during the dark period (beginning at 8:00 p.m.). Food consumption
was assessed hourly. The db/db mice were injected intraperitoneally
with 0.05 μmol/kg Mim-MBP or MBP twice daily (9:00 a.m. and
9:00 p.m.) for 2 days, followed by 5 days when no protein was adminis-
tered; this cycle was repeated four times (a total of 28 days). Food con-
sumption and body weight were measured daily at 8:00 a.m. In the
antibody neutralization test, C57BL/6J mice fasted for 24 h (08:00
a.m.–8:00 a.m.) were assigned to two groups at 11:00 a.m., and i.p.
injected with anti-human mimecan polyclonal antibody or rabbit
preimmune IgG (160 μg/g body weight). Nine hours later, all animals
were injected i.p. with Mim-MBP (0.05 μmol/kg). Cannula placement
was performed 1 week before i.c.v. injection. All rats were housed
individually, and were fasted for 12 h (8:00 p.m.–8:00 a.m.). Then,
8 μL (2 nmol/kg) Mim-MBP (3 μg/uL) or MBP (2.6 μg/uL) was injected
into the lateral ventricle. Knockoutmice andWT littermateswere fasted
for 12 h (8:00 p.m.–8:00 a.m.), followed by i.p. injection of recombinant
mouse leptin (R&D Systems, Minneapolis, MN, USA) at 5 mg/kg, or PBS
control using the same volume.
2.3. Cell Culture
For primary neuronal cell culture, the hypothalamus of 18 day SD rat
embryos were dissected in ice-cold PBS, washed three times in PBS, and
digested with 0.2% trypsin at 37 °C for 20min, followed by addition of a
DMEM/F12 medium containing 10% fetal bovine serum (FBS).
Cells were passed through a 74 μm ﬁlter, centrifuged for 7 min at
1000 rpm, and resuspended in the same medium, then seeded onto
24-well plates at 1.5 × 105 cells/well on wells coated with 100 μg/mLpoly-D-lysine (PDL, Beyotime, Shanghai, China). After 4 h, medium
was replaced with DMEM/F12 containing 2% B27 and 1× glutamine.
Forty-eight hours later, 2.5 μg/mL arabinoside (Ara-C; Sigma-Aldrich)
was added. After 24 h, medium was replaced with DMEM/F12 contain-
ing 2% B27 and 1× glutamine to remove the Ara-C. Medium was
replaced with 50% fresh medium every 3 days. On day 7, cells were
treated with 10, 50, or 100 nM recombinant mouse mimecan (R&D
Systems) for 1, 2, or 4 h, and the expression of appetite-regulation
neuropeptides and hypothalamic inﬂammatory factors was analyzed.
Cells were infected for 48 h with Murine Stem Cell Virus (MSCV)
encoding mouse mimecan. Murine microglia cell line N9 was grown in
IMDM supplemented with 5% FBS and 2 mM glutamine. Before the
experiment, cells were maintained in serum-free IMDM for 12 h.
2.4. Statistical Analysis
Analyses of data were performedwith GraphPad Prism 5.0 software.
Data were presented as means ± SEM and analyzed with the statistical
tests indicated in the text and ﬁgure legends. P b 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Mimecan is a Hormone, Abundantly Expressed in Adipose Tissue
In our previous study, we showed that mimecan is highly expressed
in themouse lung, but expressed at lower levels in other tissues, such as
adrenal, pituitary, and heart tissue (Hu et al., 2005). Using northern blot
analysis in the present study, we found that mimecan is also highly
expressed in mouse adipose tissue (Fig. 1a). Moreover, mimecan corre-
sponding to two protein bands of approximately 25 kDa and 12 kDawas
detected in the human circulation, particularly at high levels for the
form corresponding to 25 kDa (Fig. 1b). Because adipose tissue secretes
various hormones with important roles in the regulation of energy bal-
ance (Zhang et al., 1994; Scherer et al., 1995; Steppan et al., 2001;
Pelleymounter et al., 1995; Halaas et al., 1995; Campﬁeld et al., 1995),
we characterized the role(s) of mimecan in energy regulation. Firstly,
we investigated possible alterations of mimecan expression in adipose
tissue during fasting. Notably, 24 h fasting decreased mimecan mRNA
to 74% of control, and 48 h fasting reached a signiﬁcant reduction to
40% (Fig. 1c), in a similar manner as the reduction by leptin mRNA
during fasting for 48 h (Sivitz et al., 1996).
The sequence encoding the 12 kDa (residues 175–279) human
mimecan protein was inserted into the expression vector pMAL-c2x,
and the resulting fused mimecan-maltose binding protein (Mim-MBP)
was expressed in E. coli (Kapust and Waugh, 1999) and puriﬁed to
homogeneity as a 55 kDa monomer. After Mim-MBP was dissolved in
phosphate-buffered saline (PBS, pH 7.4), it was administered to
12-week-old C57BL/6J mice by intraperitoneal (i.p.) injection at doses
of 0.02, 0.05, 0.1, and 0.2 μmol/kg. Control groupswere administered ei-
ther the carrier proteinMBP at a dose of 0.2 μmol/kg, or an equal volume
of PBS. Mimecan administration resulted in a dose-dependent anorexic
effect in micewhen fasting for 12 h (Fig. 2a). There was no difference in
food intake between theMBP andPBS groups, indicating thatMBPwas a
proper control in this study. After receiving 0.02 μmol/kgMim-MBP, cu-
mulative food intake was signiﬁcantly reduced by 65.8% (0.41 ± 0.14 g
vs. 1.2± 0.27 g [mean±SEM]) for theﬁrst 3 h and 43.6% (1.33± 0.36 g
vs. 2.36 ± 0.14 g) for 8 h, compared to MBP. Furthermore, compared to
the PBS group, cumulative food intake was reduced by 83.9% (0.19 ±
0.12 g vs. 1.18 ± 0.10 g) for 3 h and 61.7% (0.86 ± 0.27 g vs. 2.25 ±
0.13 g) for 8 h after injection with 0.05 μmol/kg Mim-MBP (Fig. 2a).
With all comparisons, the anorexic effect of Mim-MBP plateaued with
a dose of 0.05 μmol/kg, hence 0.05 μmol/kg was considered a dosemax-
imal for the anorexic effect, and therefore used in subsequent experi-
ments. With ad libitum access to food, C57BL/6J mice consumed
signiﬁcantly less food over 4 h after i.p. injection of mimecan (Fig. 2b)
Fig. 1.Mimecan expressed in various mouse tissues and secreted into the blood. (a) MimecanmRNA expression in various tissues from C57BL/6J mice determined by northern blot anal-
ysis. (b) Mimecan corresponding to 25 kDa and 12 kDa was detected in human serum by western blot analysis using monoclonal antibody against mimecan. H1–H4 represents four
healthy individuals.M:molecularweightmarkers. Bodymass index (BMI) of the individuals: H1, 21.8; H2, 21.5; H3, 19.5; H4, 25.7. (c)Northernblot analysis ofmimecanmRNAexpression
in adipose tissue from C57BL/6J mice fasting for 0, 24, and 48 h (n = 4 for each time point). The right histogram is the gray scale of mimecan mRNA expression. Data are expressed as
means ± SEM. *P b 0.05 vs 0 h. Statistical analysis was performed by one-way ANOVA.
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Moreover, intracerebroventricular (i.c.v.) administration of 2 nmol/kg
Mim-MBP induced a signiﬁcant reduction in cumulative food intake
over 12 and 24 h in Sprague–Dawley (SD) rats (Fig. 2c).
To determinewhether the anorexic effect ofmimecanwas caused by
endotoxin, which has been previously shown to suppress food intake
(Gayle et al., 1998; Grossberg et al., 2011), Mim-MBP was heat-treated
at 95 °C for 5 min to denature the protein. Endotoxin is unaffected
under these conditions (Luheshi et al., 1999). Injection (i.p.) of this de-
naturedMim-MBP intomice failed to suppress food intake, and its effectFig. 2. Intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) injections of mimecan induced a
mentwith polyclonal antibody or by heat-inactivatedmimecan. (a) Cumulative food intake of C
indicated time points after 12 h of fasting (8:00 p.m.–8:00 a.m., n= 8). (b) Suppression of food
Mim-MBP (0.05 μmol/kg) (n = 5), compared to phosphate-buffered saline (PBS) or maltos
responding to i.c.v. injection of mimecan-MBP (Mim-MBP) (2 nmol/kg) (n = 8). (d) Cumu
(n = 5). (e) Antibody neutralization test in C57BL/6J mice. Mice were pretreated with pol
(f) Suppression of food intake of C57BL/6J mice responding to i.p. injection of mimecan-His (M
in (a) and (b). *P b 0.05; **P b 0.01 vs. Mim-MBP inactivated at time points in (d). Data are
one-way ANOVA.on food intake was similar to PBS. However, after injection of the Mim-
MBP without heat treatment, which came from the same container as
the heat-inactivated protein, cumulative food intake was signiﬁcantly
reduced in C57BL/6J mice (Fig. 2d). Furthermore, i.p. injection with
polyclonal antibody against mimecan signiﬁcantly attenuated the
anorexic effect of mimecan (Fig. 2e).
The 25 kDa form of mimecan could be detected in the serum from
healthy individuals in greater amounts than the 12 kDa form. To ensure
that the 25 kDa formmediated the anorexic effect, we then puriﬁed the
mimecan-His (25 kDa, residues 47–279) fusion protein (Mim-His) thatreduction in food intake and the anorexic effect of mimecan was attenuated by pretreat-
57BL/6Jmice responding to i.p. injection of different doses ofmimecan-MBP (Mim-MBP) at
intake in C57BL/6J mice with ad libitum access to food when responding to i.p. injection of
e binding protein (MBP). (c) Suppression of food intake in Spraque–Dawley (SD) rats
lative food intake of C57BL/6J mice after i.p. injection with active or inactive Mim-MBP
yclonal antibody against mimecan or rabbit preimmune IgG by i.p. injection (n = 12).
im-His) (0.05 μmol/kg) (n = 6). *P b 0.05; **P b 0.01 vs. PBS at the indicated time points
expressed as means ± SEM. *P b 0.05; **P b 0.01. Statistical analysis was performed by
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dramatic reduction in food intake (Fig. 2f). Together, these results
demonstrated that the proteins corresponding to both 25 kDa and
12 kDa could induce the reduction in food intake.
3.2. Mimecan Resulted in Reductions of Food Intake and Body Weight in
db/db and Ay/a Mice
Leptin, a hormone derived from adipose tissue, is known to inhibit
appetite (Zhang et al., 1994; Campﬁeld et al., 1995; Halaas et al., 1995;
Pelleymounter et al., 1995), but the interaction between leptin and
mimecan remains unknown. The db/db mice carrying an inactivated
leptin receptor (Chen et al., 1996) were used to investigate whether
the anorexic effect of mimecan was mediated by leptin or its receptor.
Daily food intakewas signiﬁcantly suppressed byMim-MBP administra-
tion (0.05 μmol/kg, i.p.) twice daily for 3 successive days (Fig. 3a).More-
over, mice were administered Mim-MBP twice daily for 2 successive
days, followed by 5 days off, with four repeated cycles (28 days total).
As showed in Fig. 3b, the body weight of mice treated with MBP gradu-
ally increased during the observation. However, the body weight of
mice treated with Mim-MBP was signiﬁcantly reduced during the
time when Mim-MBP was given for the ﬁrst 2 days and remained
until day 6 injection with Mim-MBP. The body weight of mice treated
with Mim-MBP also gradually increased after day 6 injection with
Mim-MBP, but the increment was less than that in the MBP-treated
control mice (Fig. 3b). These results suggested that the anorexic effect
of mimecan was independent of leptin signaling (Oh et al., 2006). Fur-
ther evidence for the anorexic effect of mimecan was obtained from
agouti mice (Ay/a), which have a locus mutation in the agouti gene in-
ducing ectopic expression of the normal agouti protein (Fan et al.,
1997). The ectopic production of agouti in the brain antagonizes
melanocortin-4 receptors, causing genetic obesity by excess food intake.Fig. 3. The anorexic effect ofmimecanwas independent of leptin andmelanocortin signaling. (a,
with ad libitum access to food (0.05 μmol/kg; i.p. injection, n= 9–10). (b) Daily bodyweight ch
squares represent the changes of body weight during mimecan-MBP or MBP treatment, respec
injections of mimecan-MBP or MBP, respectively. (c) Cumulative food intake of Ay/a mice trea
expressed as means ± SEM. *P b 0.05; **P b 0.01. Statistical analysis was performed by one-waIn Ay/amice,Mim-MBP could still reduce food intake for at least 6 h after
i.p. injection (Fig. 3c), showing that the mimecan-induced anorexia did
not depend on melanocortin signaling, which is the most important
pathway mediating appetite control.3.3. Mimecan increased IL-1Β and IL-6 mRNA expressions in the hypothal-
amus and N9 microglia
Previous studies have shown that IL-1β and IL-6 are the downstream
effectors of leptin signaling in reducing food intake, and i.c.v. injection of
IL-1β and IL-6 per se suppresses food intake (Luheshi et al., 1999;
Scarlett et al., 2007; Schele et al., 2012). Therefore, we investigated the
effect of mimecan on the hypothalamic cytokine proﬁle. Notably, com-
pared with mice treated with Mim-MBP inactivated by boiling, mRNA
expression of IL-1β and IL-6was signiﬁcantly increased in the hypothal-
amus from mice injected i.p. with Mim-MBP (Fig. 4a). Consistent with
increased IL-6 and IL-1β, the intracellular signal protein, SOCS3, a
negative-feedback regulator of leptin signaling (Mori et al., 2004), was
also elevated in hypothalamus. Unexpectedly, there was no signiﬁcant
increase in the mRNA expressions of IL-6, IL-1β, and SOCS3 in primary
cultured hypothalamic neurons that were either transfected with
MSCV-mimecan or treated with recombinant mouse mimecan (rm
Mim) (Fig. S2), although the expression of IL-1βwas slightly increased
by the latter treatment. However, it has been reported that not only
neurons, but also the microglia in the hypothalamus secrete cytokines
regulating energy balance (Tang et al., 2007; Le Foll et al., 2014). In
the present study, we found that in themousemicroglia cell line N9, in-
cubation with recombinant mouse mimecan also resulted in an induc-
tion of IL-6 and IL-1β (Fig. 4b), suggesting that the cellular machinery
required for interleukin induction was present in the brain, and mainly
in the microglia.b) Effect ofmimecanon daily food intake (a) and bodyweight increment (b) in db/dbmice
ange (g)= bodyweight on the indicated day— bodyweight on day 0. The solid circles and
tively. The empty circles and squares represent the changes of body weight after stopping
ted with Mim-MBP (0.05 μmol/kg) after fasting for 6 h (i.p. injection, n = 4–5). Data are
y ANOVA.
Fig. 4. Effect of mimecan on IL-1β, IL-6, and SOCS3 expression and features of mimecan knockout mice. (a) The mRNA expression of IL-1β, IL-6, and SOCS3 in the hypothalamus from
C57BL/6J mice (n= 10) with ad libitum access to food, treatedwith active or inactive Mim-MBP (0.05 μmol/kg) by i.p. injection for 4 h. The reference genewas actin. (b) Effect of recom-
binantmousemimecan (rmMim) (100nM for 4 h) on the expression of IL-1β, SOCS3, and IL-6 inN9microglia cells. The reference genewas actin. (c, d) The bodyweight (c) and daily food
intake (d) inMin−/− (knockout) mice and wild type (WT) littermates with ad libitum access to food (n= 25). (e) Leptin mRNA expression in adipose tissue fromMin−/−mice and WT
littermates (n = 4). (f) Levels of leptin in serum fromMim−/−mice andWT littermates (n = 12). Data are expressed as means ± SEM. *P b 0.05; **P b 0.01. Statistical analysis was per-
formed by one-way ANOVA.
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leptin expression
To further explore the physiological role of mimecan in energy ho-
meostasis, we conducted subsequent experiments using mimecan
knockout mice (Mim−/−) (Ma et al., 2011). Mimecan deﬁciency did
not inﬂuence the growth or reproduction of these mice. Unexpectedly,
there was no signiﬁcant difference in body weight or food intake be-
tween Mim−/− mice and wild-type (WT) littermates, regardless of
whether the animals were fed a standard diet or a high fat diet (Figs.
4c, d and S3). Notably, the levels of leptin in adipose tissue (Fig. 4e)
and serum (Fig. 4f) were higher in Mim−/− mice fed standard diet
than in WT littermates, which may explain the absence of orexigenic
and obese phenotypes inMim−/−mice. Moreover, the anorexic effect
of leptin was partially attenuated inMim−/−mice compared with WT
mice (Fig. S4).4. Discussion
Mimecan is extensively expressed in various tissues including bone,
cornea, lung, and various other tissues. In the present study, we found
mimecan was highly expressed in the adipose tissue as a hormone,
was secreted into the circulation. Administration of mimecan by intra-
peritoneal or intracerebroventricular injection inhibited food intake in
a dose-dependent manner in C57BL/6J mice and SD rats, and the an-
orexic effect was attenuated by pretreatment with polyclonal antibody
against mimecan. These results suggested that mimecan is a hormone,
playing important roles in the regulation of food intake.
Mimecan could induce anorexia either by i.p. injection or by i.c.v. in-
jection.Moreover, much lower doses ofmimecanwere required to elicit
anorexic effect when injected centrally than peripherally, suggesting
mimecan may exert its anorexic effect in the central nervous system
(CNS). It has been shown that the hypothalamus is the major centercontrolling energymetabolism. During the last decade, accumulated ev-
idence supports the hypothesis that both IL-1β and IL-6 play integral
roles in the regulation of energy metabolism at the level of the CNS.
Several previous studies have shown that IL-1, IL-6, and their respective
receptors are locally produced in the hypothalamus (Scarlett et al., 2007;
Schele et al., 2012; Shirazi et al., 2013). Mice lacking either IL-1R or IL-6
develop late-onset obesity, and intracerebroventricular rather than in-
traperitoneal IL-6 treatment decreases obesity in obese IL6−/− mice
(Garcia et al., 2006; Wallenius et al., 2002). Moreover, central injection
of IL-1 or IL-6 induces a marked suppression of appetite (DeBoer et al.,
2009; Schobitz et al., 1995) and a recent study reported that IL-1β and
IL-6 mediate GLP-1 induced anorexia in the hypothalamus (Shirazi
et al., 2013). Notably, compared to mice treated with mimecan dena-
tured by boiling, the expression of IL-1β and IL-6 in the hypothalamus
was signiﬁcantly increased after the injection of mimecan without heat
treatment. It has been proposed that the effect of mimecan on feeding
behavior maybe mediated via the IL-1β and IL-6 pathway in the CNS,
which resembles GLP-1 induced anorexia (Shirazi et al., 2013). In the
present study, we detected the induction of IL-1β and IL-6 by mimecan
in microglia rather than primary hypothalamic neuronal cells. Further-
more, a previous study showed that IL-6 production occurs selectively
inmicroglia rather than in neurons or astrocytes from the hypothalamus
and cerebral cortex (Le Foll et al., 2014). Moreover, it was reported that
leptin could induce IL-6 production in microglia mediated by the leptin
receptor, insulin receptor substrate-1, and the phosphatidylinositol-3-
kinase pathway (Tang et al., 2007). A recent study reported that
amylin-induced IL-6 production in microglia from the ventromedial hy-
pothalamus mediates anorexia via enhanced leptin signaling (Le Foll
et al., 2014). Together, our results and previous reports strongly suggest
that mimecan-induced anorexia is mediated by IL-1β and IL-6.
Although considerable data suggest that central IL-1β and IL-6 can
regulate food intake during health conditions (Wallenius et al., 2002;
Garcia et al., 2006; Shirazi et al., 2013), IL-1β and IL-6, as inﬂammatory
factors, also play key roles in lipopolysaccharide ([LPS] endotoxin)
1723H.-M. Cao et al. / EBioMedicine 2 (2015) 1718–1724-induced anorexia (Gayle et al., 1998; Grossberg et al., 2011).Thus, it is
questionable whether the anorexic effect of mimecan is elicited by en-
dotoxin, which may be a contaminant in the protein prepared from a
prokaryotically expressed vectors (Kalra et al., 1991).
The following experiments conﬁrmed the speciﬁc anorexic effect of
mimecan. Heat-denatured mimecan with minimal denaturation of en-
dotoxin failed to reduce food intake and induce IL-1β and IL-6 expres-
sion in the hypothalamus (Luheshi et al., 1999), but the injection of
mimecan without heat treatment retained activity. Moreover, both
IL-1β and IL-6 were induced in the microglia by recombinant mouse
mimecan (R&D, Minneapolis MN, USA), which was puriﬁed from a eu-
karyotic expression system. In addition, mimecan-induced inhibition
of food intake was signiﬁcantly attenuated with polyclonal antibody
pretreatment, again conﬁrming that the anorexic effect resulted from
mimecan rather than from the endotoxin.
Leptin was the ﬁrst identiﬁed adipose-derived hormone that regu-
lates food intake. Because mimecan is an anorexic hormone abundantly
expressed in adipose tissue, similar to the characteristics of leptin, we
further investigated the correlation between mimecan and leptin. In
db/db mice, where the function of the leptin receptor is genetically
deleted, mimecan-induced reduction of food intake was still observed,
showing that the anorexic effect of mimecan at least partially involved
an independent pathway from leptin signaling. Mim−/−mice showed
a similar food intake and body weight compared to WT litters, regard-
less of whether the animals were fed a standard diet or a high fat diet.
Importantly, leptin was signiﬁcantly increased in either mRNA expres-
sion in adipose tissue or serum levels in the circulation from Mim−/−
mice. Considering the notable anorexic effect of leptin, the absence of
orexigenic and obese phenotypes in Mim−/− mice may be due to the
higher levels of expression and secretion of leptin. Moreover, leptin-
induced inhibition of food intake in Mim−/− mice involved a slight
attenuation compared to WT litters, showing that mimecan is not es-
sential for leptin-induced anorexia. Taken together, our results suggest
that mimecan and leptin use two independent peripheral signal
pathways that regulate food metabolism.
In conclusion, mimecan is a hormone highly expressed in adipose
tissue and secreted into the circulation. Mimecan exhibits an anorexic
effect, possibly by increasing IL-1β and IL-6 expression in the hypothal-
amus, and its anorexic effect differs from the mechanism of action of
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